Ocrevus 300 MG/10 ML vial 10ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQV1J
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $128,189
Award facts
- Contract value 100% obligated
- $128,188.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 22, 2026, for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $128,188.50. This firm fixed-price contract, with an ultimate completion date of February 12, 2026, represents a task order issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2031. The award is not designated as a set-aside and was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. Ocrevus, a specialty pharmaceutical product used in the treatment of multiple sclerosis, falls within the company's established portfolio of supplying neurological and specialty medications to federal military healthcare systems.
This delivery order exemplifies the critical role that AmerisourceBergen plays as a pharmaceutical prime vendor within the Defense Health Enterprise. The DLA Troop Support Medical's pharmaceutical supply chain relies on delivery orders such as this to fulfill the medical needs of military treatment facilities and veteran healthcare programs worldwide. AmerisourceBergen's demonstrated capability to compete successfully and deliver specialized pharmaceutical products through firm fixed-price arrangements reflects its position as a key provider of essential medical commodities to federal healthcare systems.
Quick answers
Who was awarded contract SPE2DR26FQV1J?
SPE2DR26FQV1J was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FQV1J worth?
The government has obligated $128,189 on SPE2DR26FQV1J.
Is contract SPE2DR26FQV1J an order under another contract?
Yes. SPE2DR26FQV1J is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQV1J competed?
The extent of competition for SPE2DR26FQV1J was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award